earnings
confidence high
sentiment positive
materiality 0.85
Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance
GILEAD SCIENCES, INC.
2024-Q3 EPS reported
-$1.04
revenue$21,185,000,000
- GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.
- Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).
- Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.
- Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.
- Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY.